Skip to content

Preclinical study of human OX/ MD / FA gene methylation detection kit (PCR fluorescence probe method) for auxiliary diagnosis of liver cancer

Preclinical study of human OX/ MD / FA gene methylation detection kit (PCR fluorescence probe method) for auxiliary diagnosis of liver cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100046247
Enrollment
Unknown
Registered
2021-05-12
Start date
2021-05-11
Completion date
Unknown
Last updated
2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Gold Standard:The clinical diagnosis method of liver cancer in the code for diagnosis and treatment of primary liver cancer (2019 Edition) of oncology branch of Chinese Medical Association was adopted

Sponsors

Hunan people's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Willing to sign informed consent; 2. Aged 18 to 80 years, male or female; 3. No previous history of malignant tumor; 4. One of the following diseases: malignant solid tumor of digestive system: primary hepatocellular carcinoma (excluding mixed hepatobiliary carcinoma), metastatic hepatocellular carcinoma, cholangiocarcinoma, pancreatic cancer, gastric cancer, etc; Hepatic cavernous hemangioma and other benign tumors; Liver cirrhosis, chronic hepatitis B, chronic hepatitis C; 5. Tumor patients should be newly diagnosed and have not received any anti-tumor treatment, including but not limited to surgery, radiotherapy, chemotherapy, etc; 6. The relevant information of the sample is complete, including subject number, sample type, hospitalization number, age, gender, sample collection time, clinical diagnosis, etc; 7. The volume of blood sample shall not be less than 10ml.

Exclusion criteria

Exclusion criteria: 1. They did not meet the inclusion criteria; 2. Pregnant or lactating women; 3. The subjects received allogeneic blood transfusion or cell therapy within one year; 4. The subjects had received organ transplantation in the last 3 months; 5. There are two or more primary malignant tumors from different organs and tissues at the same time; 6. Anemia or severe blood loss in recent one month; 7. Failure to express personal wishes or mental illness may affect the compliance of the program; 8. The researcher thinks that it is not suitable to participate in this study; 9. Hemolysis occurred during blood sample collection.

Design outcomes

Primary

MeasureTime frame
cell-free DNA;

Countries

China

Contacts

Public ContactZheng Jiao

Hunan Provincial People's Hospital

kybgcp@163.com+86 731 83929310

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026